Billie Ann Radcliffe, Yongbok Kim, Julie Raffi, Diandra N Ayala-Peacock, Sarah J Stephens, Junzo Chino, Sheridan Meltsner, Oana Craciunescu
{"title":"局部晚期宫颈癌患者 HDR 近距离放射治疗剂量计算方法的回顾性评估：AcurosBV 与 AAPM TG43 形式化对比。","authors":"Billie Ann Radcliffe, Yongbok Kim, Julie Raffi, Diandra N Ayala-Peacock, Sarah J Stephens, Junzo Chino, Sheridan Meltsner, Oana Craciunescu","doi":"10.1002/acm2.14549","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective analysis was completed to investigate the use of a model-based dose calculation algorithm (MBDCA) AcurosBV, for use in HDR BT treatments for locally advanced cervical cancer treated with tandem and ovoid applicators with interstitial needles.</p><p><strong>Methods: </strong>A cohort of 32 patients receiving post-EBRT HDR brachytherapy boost with a prescription dose of 5.5 Gy × 5 fractions to the high-risk clinical target volume (CTV<sub>HR</sub>) were selected for this study. For standard TG43 dose calculation, applicators were manually digitized on the planning images, while for AcurosBV calculations, solid renderings of Titanium Fletcher Suite Delclos (FSD) applicators included in BrachyVision were matched to those used clinically and Ti needles were manually digitized. The dose was recalculated using Varian's AcurosBV 13.5 and dose-to-medium-in-medium (D<sub>m,m</sub>) was reported. EQD2 values for targets and organs at risk were compared between dose calculation formalisms. D<sub>90%</sub> and D<sub>98%</sub> values were reported for the high and intermediate-risk CTVs, and <math> <semantics> <msub><mrow><mspace></mspace> <mi>D</mi></mrow> <mrow><mrow><mn>2</mn> <mspace></mspace> <mi>c</mi></mrow> <msup><mi>m</mi> <mn>3</mn></msup> </mrow> </msub> <annotation>${\\mathrm{\\ D}}_{{\\mathrm{2\\ c}}{{\\mathrm{m}}}^{\\mathrm{3}}}$</annotation></semantics> </math> values were reported for OARs including bladder, rectum, sigmoid, bowel, and vagina. Due to variability within the patient cohort, the dosimetric impact of AcurosBV was investigated corresponding to planning image modality (CT vs. CBCT), presence of Ti needles, and contrast within vaginal balloons used to stabilize implants. AcurosBV showed lower dosimetric values for all plans compared to TG43.</p><p><strong>Results: </strong>The average ± standard deviation of dosimetric reduction in D<sub>90%</sub> was 4.33 ± 0.09% for CTV<sub>HR</sub> and 4.12 ± 0.09% for CTV<sub>IR</sub>. The reduction to OARs <math> <semantics> <msub><mrow><mspace></mspace> <mi>D</mi></mrow> <mrow><mrow><mn>2</mn> <mspace></mspace> <mi>c</mi></mrow> <msup><mi>m</mi> <mn>3</mn></msup> </mrow> </msub> <annotation>${\\mathrm{\\ D}}_{{\\mathrm{2\\ c}}{{\\mathrm{m}}}^{\\mathrm{3}}}$</annotation></semantics> </math> was: 4.99 ± 0.15% for bladder, 7.87 ± 0.16% for rectum, 5.79 ± 0.17% for sigmoid, 6.91 ± 0.14% for bowel, and 4.55 ± 0.14% for vagina.</p><p><strong>Conclusions: </strong>AcurosBV should be utilized for HDR BT GYN cases, treated with tandem and ovoid applicators, with high degrees of heterogeneity and calculated in tandem with TG43.</p>","PeriodicalId":14989,"journal":{"name":"Journal of Applied Clinical Medical Physics","volume":" ","pages":"e14549"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism.\",\"authors\":\"Billie Ann Radcliffe, Yongbok Kim, Julie Raffi, Diandra N Ayala-Peacock, Sarah J Stephens, Junzo Chino, Sheridan Meltsner, Oana Craciunescu\",\"doi\":\"10.1002/acm2.14549\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This retrospective analysis was completed to investigate the use of a model-based dose calculation algorithm (MBDCA) AcurosBV, for use in HDR BT treatments for locally advanced cervical cancer treated with tandem and ovoid applicators with interstitial needles.</p><p><strong>Methods: </strong>A cohort of 32 patients receiving post-EBRT HDR brachytherapy boost with a prescription dose of 5.5 Gy × 5 fractions to the high-risk clinical target volume (CTV<sub>HR</sub>) were selected for this study. For standard TG43 dose calculation, applicators were manually digitized on the planning images, while for AcurosBV calculations, solid renderings of Titanium Fletcher Suite Delclos (FSD) applicators included in BrachyVision were matched to those used clinically and Ti needles were manually digitized. The dose was recalculated using Varian's AcurosBV 13.5 and dose-to-medium-in-medium (D<sub>m,m</sub>) was reported. EQD2 values for targets and organs at risk were compared between dose calculation formalisms. D<sub>90%</sub> and D<sub>98%</sub> values were reported for the high and intermediate-risk CTVs, and <math> <semantics> <msub><mrow><mspace></mspace> <mi>D</mi></mrow> <mrow><mrow><mn>2</mn> <mspace></mspace> <mi>c</mi></mrow> <msup><mi>m</mi> <mn>3</mn></msup> </mrow> </msub> <annotation>${\\\\mathrm{\\\\ D}}_{{\\\\mathrm{2\\\\ c}}{{\\\\mathrm{m}}}^{\\\\mathrm{3}}}$</annotation></semantics> </math> values were reported for OARs including bladder, rectum, sigmoid, bowel, and vagina. Due to variability within the patient cohort, the dosimetric impact of AcurosBV was investigated corresponding to planning image modality (CT vs. CBCT), presence of Ti needles, and contrast within vaginal balloons used to stabilize implants. AcurosBV showed lower dosimetric values for all plans compared to TG43.</p><p><strong>Results: </strong>The average ± standard deviation of dosimetric reduction in D<sub>90%</sub> was 4.33 ± 0.09% for CTV<sub>HR</sub> and 4.12 ± 0.09% for CTV<sub>IR</sub>. The reduction to OARs <math> <semantics> <msub><mrow><mspace></mspace> <mi>D</mi></mrow> <mrow><mrow><mn>2</mn> <mspace></mspace> <mi>c</mi></mrow> <msup><mi>m</mi> <mn>3</mn></msup> </mrow> </msub> <annotation>${\\\\mathrm{\\\\ D}}_{{\\\\mathrm{2\\\\ c}}{{\\\\mathrm{m}}}^{\\\\mathrm{3}}}$</annotation></semantics> </math> was: 4.99 ± 0.15% for bladder, 7.87 ± 0.16% for rectum, 5.79 ± 0.17% for sigmoid, 6.91 ± 0.14% for bowel, and 4.55 ± 0.14% for vagina.</p><p><strong>Conclusions: </strong>AcurosBV should be utilized for HDR BT GYN cases, treated with tandem and ovoid applicators, with high degrees of heterogeneity and calculated in tandem with TG43.</p>\",\"PeriodicalId\":14989,\"journal\":{\"name\":\"Journal of Applied Clinical Medical Physics\",\"volume\":\" \",\"pages\":\"e14549\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Applied Clinical Medical Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/acm2.14549\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Clinical Medical Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/acm2.14549","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism.
Purpose: This retrospective analysis was completed to investigate the use of a model-based dose calculation algorithm (MBDCA) AcurosBV, for use in HDR BT treatments for locally advanced cervical cancer treated with tandem and ovoid applicators with interstitial needles.
Methods: A cohort of 32 patients receiving post-EBRT HDR brachytherapy boost with a prescription dose of 5.5 Gy × 5 fractions to the high-risk clinical target volume (CTVHR) were selected for this study. For standard TG43 dose calculation, applicators were manually digitized on the planning images, while for AcurosBV calculations, solid renderings of Titanium Fletcher Suite Delclos (FSD) applicators included in BrachyVision were matched to those used clinically and Ti needles were manually digitized. The dose was recalculated using Varian's AcurosBV 13.5 and dose-to-medium-in-medium (Dm,m) was reported. EQD2 values for targets and organs at risk were compared between dose calculation formalisms. D90% and D98% values were reported for the high and intermediate-risk CTVs, and values were reported for OARs including bladder, rectum, sigmoid, bowel, and vagina. Due to variability within the patient cohort, the dosimetric impact of AcurosBV was investigated corresponding to planning image modality (CT vs. CBCT), presence of Ti needles, and contrast within vaginal balloons used to stabilize implants. AcurosBV showed lower dosimetric values for all plans compared to TG43.
Results: The average ± standard deviation of dosimetric reduction in D90% was 4.33 ± 0.09% for CTVHR and 4.12 ± 0.09% for CTVIR. The reduction to OARs was: 4.99 ± 0.15% for bladder, 7.87 ± 0.16% for rectum, 5.79 ± 0.17% for sigmoid, 6.91 ± 0.14% for bowel, and 4.55 ± 0.14% for vagina.
Conclusions: AcurosBV should be utilized for HDR BT GYN cases, treated with tandem and ovoid applicators, with high degrees of heterogeneity and calculated in tandem with TG43.
期刊介绍：
Journal of Applied Clinical Medical Physics is an international Open Access publication dedicated to clinical medical physics. JACMP welcomes original contributions dealing with all aspects of medical physics from scientists working in the clinical medical physics around the world. JACMP accepts only online submission.
JACMP will publish:
-Original Contributions: Peer-reviewed, investigations that represent new and significant contributions to the field. Recommended word count: up to 7500.
-Review Articles: Reviews of major areas or sub-areas in the field of clinical medical physics. These articles may be of any length and are peer reviewed.
-Technical Notes: These should be no longer than 3000 words, including key references.
-Letters to the Editor: Comments on papers published in JACMP or on any other matters of interest to clinical medical physics. These should not be more than 1250 (including the literature) and their publication is only based on the decision of the editor, who occasionally asks experts on the merit of the contents.
-Book Reviews: The editorial office solicits Book Reviews.
-Announcements of Forthcoming Meetings: The Editor may provide notice of forthcoming meetings, course offerings, and other events relevant to clinical medical physics.
-Parallel Opposed Editorial: We welcome topics relevant to clinical practice and medical physics profession. The contents can be controversial debate or opposed aspects of an issue. One author argues for the position and the other against. Each side of the debate contains an opening statement up to 800 words, followed by a rebuttal up to 500 words. Readers interested in participating in this series should contact the moderator with a proposed title and a short description of the topic
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
